Relation of neuropathology with cognitive decline among older persons without dementia by Patricia A. Boyle et al.
“fnagi-05-00050” — 2013/9/5 — 20:25 — page 1 — #1
ORIGINAL RESEARCH ARTICLE
published: 09 September 2013
doi: 10.3389/fnagi.2013.00050
Relation of neuropathology with cognitive decline among
older persons without dementia
Patricia A. Boyle1,2*, LeiYu1,3, Robert S.Wilson1,2,3, Julie A. Schneider1,3,4 and David A. Bennett1,3
1 Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA
2 Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA
3 Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
4 Department of Pathology, Rush University Medical Center, Chicago, IL, USA
Edited by:
Orly Lazarov, The University of Illinois
at Chicago, USA
Reviewed by:
Patrick R. Hof, Mount Sinai School of
Medicine, USA
JunmingWang, University of
Mississippi Medical Center, USA
*Correspondence:
Patricia A. Boyle, Rush Alzheimer’s
Disease Center, Rush University
Medical Center, 600 South Paulina,
Suite 1020B, Chicago, IL 60612, USA
e-mail: patricia_boyle@rush.edu
Objective: Although it is now widely accepted that dementia has a long preclinical phase
during which neuropathology accumulates and cognition declines, little is known about the
relation of neuropathology with the longitudinal rate of change in cognition among older
persons without dementia.We quantiﬁed the burden of the neuropathologies of the three
most common causes of dementia [i.e., Alzheimer’s disease (AD), cerebrovascular disease
(CVD), and Lewy body disease (LBD)] and examined their relation with cognitive decline in
a large cohort of persons without dementia proximate to death.
Methods: A total of 467 deceased participants without dementia from two longitudinal
clinical-pathologic studies, Rush Memory and Aging Project and Religious Orders Study,
completed a mean of 7 annual evaluations including 17 cognitive tests. Neuropathologic
examinations provided quantitativemeasures ofAD (i.e., amyloid load, tangle density), CVD
(i.e., macroscopic infarcts, microinfarcts), and neocortical Lewy bodies. Randomcoefﬁcient
models were used to examine the relation of the neuropathologies with rates of global
cognitive decline as well as decline in four speciﬁc cognitive systems.
Results: At autopsy, 82% of persons without dementia had amyloid, 100% had tangles,
29% had macroscopic infarcts, 25% had microinfarcts, and 6% had neocortical Lewy
bodies. Global cognition declined a mean of 0.034 unit per year (SE = 0.003, p < 0.001).
In separate analyses, amyloid, tangles (p-values <0.001) and neocortical Lewy bodies
(p = 0.015) were associated with an increased rate of global cognitive decline; macroscopic
infarcts and microinfarcts were not. Further, when analyzed simultaneously, amyloid,
tangles, and neocortical Lewy bodies remained associated with global cognitive decline
(p-values <0.024). Finally, measures of AD were associated with decline in three of four
systems, including episodic memory (i.e., tangles), semantic memory (i.e., amyloid and
tangles), and working memory (i.e., amyloid). Lewy bodies also were associated with
decline in three of four systems (i.e., semantic memory, working memory, and perceptual
speed).
Interpretation:The neuropathologies of the common causes of dementia, particularly AD
and neocortical LBD, are associated with decline in multiple cognitive abilities among older
persons without dementia.
Keywords: cognitive aging, Alzheimer’s disease, neuropathology, vascular disease, Lewy bodies
INTRODUCTION
It is nowwidely recognized that dementia is characterized by a long
preclinical phase during which neuropathology accumulates and
cognition declines, and an understanding of the preclinical phase
is urgently needed to combat the public health challenge posed by
cognitive decline in old age (Sperling et al., 2011). We and others
have shown that the neuropathologies of the three most common
causes of dementia,Alzheimer’s disease (AD), cerebrovascular dis-
ease (CVD), andLewybody disease (LBD), are frequently observed
in the brains of older persons without dementia and related to the
level of cognition proximate to death (Crystal et al., 1988; Katzman
et al., 1988; Riley et al., 2002; Knopman et al., 2003; Bennett et al.,
2006a, 2012c; Sonnen et al., 2007; ). To date, however, few studies
have examined the relation of neuropathology with longitudinal
rates of cognitive decline among older persons without demen-
tia, and ﬁndings are mixed (Green et al., 2000; Galvin et al., 2005;
Driscoll et al., 2006; Balasubramanian et al., 2012). Moreover, the
studies that examined the relation of neuropathology with cogni-
tive decline focused on a single neuropathology (i.e., AD), despite
evidence that mixed neuropathologies are common and are most
strongly associated with cognitive impairment (Schneider et al.,
2007). An understanding of the relation of the neuropathologies
of the common causes of dementia with longitudinal rates of cog-
nitive decline among persons without dementia has implications
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for efforts to reduce the public health burden posed by cognitive
decline in old age.
In this study, we examined the relation of the neuropathologies
of AD, CVD, and LBD, with longitudinal rates of cognitive decline
among 467 older persons who were free of dementia at the time
of death. Participants were from two large cohort studies of aging,
the Rush Memory and Aging Project and the Religious Orders
Study, and had detailed annual cognitive function data available
for up to 18 years (Bennett et al., 2012a,b). All underwent autopsies
that yielded quantitative measures of multiple neuropathologies,
including measures of AD (i.e., amyloid load, tangle density),
CVD (i.e., macroscopic infarcts, microinfarcts), and neocortical
Lewy bodies (Bennett et al., 2006a, 2012c; Arvanitakis et al., 2011;
Schneider et al., 2012). Random coefﬁcient models were used to
characterize linear rates of cognitive decline and examine the rela-
tion of the neuropathologies with decline in global cognition and
four speciﬁc cognitive systems (Laird and Ware, 1982).
MATERIALS AND METHODS
PARTICIPANTS
Participants were from two clinical–pathologic cohort studies of
aging, the Religious Orders Study and the Memory and Aging
Project (Bennett et al., 2012a,b). TheReligiousOrders Study began
in 1994 and involves older Catholic nuns, priests, andmonks from
more than 40 groups across the United States. The Rush Memory
and Aging Project began in 1997 and involves older lay persons
from retirement communities and subsidized housing facilities in
the Chicago metropolitan area. All participants agreed to annual
clinical evaluations and brain autopsy at death. Written informed
consent was obtained in each study after procedures were fully
explained, and both studies were approved by the Institutional
Review Board of Rush University Medical Center. The follow
up participation rates exceed 95% of survivors and autopsy rates
exceed 80%. At the time of these analyses, data were available from
467 non-demented deceased persons with at least two cognitive
evaluations.
CLINICAL AND COGNITIVE EVALUATION PROCEDURES
Participants in both studies underwent structured, annual clinical
evaluations that included detailed cognitive and neurologic exam-
inations, as previously reported (Bennett et al., 2012a,b). The two
studies have 19 cognitive tests in common. Scores from 17 of those
tests were converted to z scores using the mean and standard devi-
ation of the cohort at baseline, and z-scores were averaged to yield
a summarymeasure of global cognition (Bennett et al., 2012a,b,c).
The use of a composite score has the advantage of minimizing ﬂoor
and ceiling effects and other sources of random variability and is
preferable for studies examining longitudinal rates of change in
cognition.
BRAIN AUTOPSY PROCEDURES AND QUANTIFICATION OF PATHOLOGY
MEASURES
Brains were removed, weighed, and immersion ﬁxed in 4%
paraformaldehyde for at least 72 h. One centimeter coronal slabs of
brain from both hemispheres were grossly inspected and pathol-
ogy was recorded, as previously described (Bennett et al., 2006a,
2012a,b,c; Arvanitakis et al., 2011; Schneider et al., 2012). After
gross examination, nine brain regions of interest (i.e., midfrontal,
midtemporal, inferior parietal, anterior cingulate, entorhinal and
hippocampal cortices, basal ganglia, thalamus, and midbrain)
were dissected from the 1-cm slabs of ﬁxed tissue and processed
and embedded in parafﬁn. Sections (6 μm) from the paraf-
ﬁn blocks were stained with hematoxylin and eosin for general
pathology including microscopic infarcts. In addition, multiple
tissue blocks from eight brain regions (i.e., entorhinal cortex,
CA1/subiculum of the hippocampus, superior frontal cortex, dor-
solateral prefrontal cortex, inferior temporal cortex, angular gyrus,
anterior cingulate cortex, andoccipital cortex)were cut into 20μm
sections to immunohistochemically identify and quantify amyloid
load and PHFtau positive tangle density.
Amyloid-β was labeled with an N-terminus–directed mono-
clonal antibody in eight brain regions (described above; 10D5;
Elan, Dublin, Ireland; 1:1,000), as previously described (Schneider
et al., 2007, 2012; Arvanitakis et al., 2011). Immunohistochem-
istry was performed using diaminobenzidine as the reporter, with
2.5% nickel sulfate to enhance immunoreaction product contrast.
Brieﬂy, the brain region of interest was outlined at low power using
StereoInvestigator software version 9 (MicroBrightﬁeld, Colch-
ester,VT,USA) and anOlympus (Tokyo, Japan) BX-51microscope
with an attachedmotorized stage. A gridwas randomly placed over
the outlined area. Following camera and illumination calibration,
the magniﬁcation was raised to the 20× objective, and images at
each sampling site were obtainedwith amotorized stage. Quantiﬁ-
cation of amyloid-β load was accomplished by image processing
in an automated, multistage computational image analysis proto-
col. Mean fraction (percentage area positive for amyloid) per brain
region and per subject was computed.
PHFtau was labeled with an antibody speciﬁc for phospho-
rylated tau (AT8; Innogenetics, San Ramon, CA, USA; 1:1,000)
in all eight brain regions. Quantiﬁcation of tangle density was
accomplished with the stereological mapping station. Brieﬂy, after
the brain region of interest was delimited at low power, a grid
was randomly placed over the entire brain region by the software
program. Magniﬁcation was raised to the 40× objective, and the
program was engaged to direct the motorized stage to stop at each
intersection point of the grid for sampling. All objects within the
150μm× 150μmcounting frame that did not touch the exclusion
lines of the box (bottom and left sides) were counted. Quantiﬁ-
cation of tangle density was done via the stereological mapping
station and yielded a measure of the density of tangles (per mm2)
that was averaged within and across brain regions.
For each brain, the age, volume (in cubic millimeters), and
anatomic location of all macroscopic cerebral infarctions were
identiﬁed in both hemispheres. All macroscopic infarcts were
dissected, parafﬁn embedded and cut and stained, allowing for
conﬁrmation of the lesion. Age and locations of old microinfarcts,
deﬁned as infarcts seen on microscopy but not identiﬁed on gross
examination, were based on analysis of sections from nine regions
of a single hemisphere.Macroscopic and microscopic infarctions
were analyzed as dichotomous variables (i.e., present/absent; Riley
et al., 2002; Schneider et al., 2007, 2012).
Neocortical Lewy bodies were identiﬁed with an antibody to α-
synuclein, and only intracytoplasmic Lewy bodies were used as an
indicator of positive staining. To simplify criteria for the different
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types of Lewy body pathology, the McKeith criteria were modiﬁed
such that nigral predominant Lewy body pathology included cases
with Lewy bodies in the substantia nigra without evidence of
Lewy bodies in the limbic or neocortical regions. Limbic-type
LBD included cases with either anterior cingulate or entorhinal
positivity (typically also with nigral pathology) without neocor-
tical Lewy body pathology. Finally neocortical-type Lewy body
pathology required Lewy bodies in either midfrontal, temporal, or
inferior parietal cortex with either nigral or limbic positivity, but
often with both. Each case was classiﬁed as 0 = no Lewy bodies,
1 = nigral predominant, 2 = limbic-type, or 3 = neocortical-type
Lewy body pathology. Neocortical Lewy body pathology was used
in these analyses as a dichotomous variable (i.e., present/absent)
given the strong association of neocortical Lewy body pathology
with cognition.
STATISTICAL ANALYSES
We ﬁrst describe the characteristics of the participants. Next, we
used random coefﬁcientmodels to characterize linear rates of cog-
nitive decline and examine the relation of neuropathology with
cognitive decline (Laird andWare, 1982). We began with an initial
modelwith terms for age, sex, education, time, and the interactions
of time with the demographic variables; time is deﬁned as the time
(in years) prior to death. The estimate for time (i.e., the slope) cor-
responds to the mean rate of decline in cognition. We then added
in terms for the neuropathologies and their interactions with time
in a series of models. Each signiﬁcant time-by-neuropathology
term characterizes the difference from the mean slopes of cog-
nitive decline associated with the neuropathology studied. The
core (fully adjusted) model included terms for age, sex, education,
time, all of the neuropathologies, and the interactions of time with
all demographic and neuropathologic variables. Finally, because
it is possible that regionally speciﬁc neuropathology may have
differential effects on cognitive decline among persons without
dementia, we next examined the relation of the neuropathologies
with decline in cognition in a series of models examining mesial
temporal and neocortical amyloid and tangles, respectively; the
measures of amyloid and tangles were examined in separate mod-
els given their high correlations (Spearman r for mesial temporal
and neocortical amyloid= 0.91, p< 0.001 and formesial temporal
and neocortical tangles = 0.61, p < 0.001) and all analyses con-
trolled for the presence of CVDandLBD.Analyseswere performed
in SAS®9.2(SAS Institute Inc., Cary, NC, USA).
RESULTS
DESCRIPTIVES
Participants (n = 467) in these analyses completed a mean of 7.0
(SD= 3.7, range= 2–18) years of annual cognitive function testing
and were an average of 87 (SD = 6.5, range = 66–106) years of
age at the time of death; additional descriptive data are provided
in Table 1. The distribution of the global cognitive measure at
baseline was approximately normal (mean = 0.07, SD = 0.45).
At autopsy, 382 (82%) of persons were positive for amyloid, 467
(100%) were positive for tangles, 133 (29%) had one or more
macroscopic infarcts, 117 (25%) had one or more microinfarcts,
and 29 (6%) had neocortical Lewy bodies.
Table 1 | Descriptive characteristics of the cohort.
Variable Mean, SD, range (or # and percent)
Age at death 87, 6.5, 66–106
Education 16.2, 3.6, 5–30
% Female 295, 63%
%White, non-Hispanic 446, 96%
Baseline MMSE 28.2, 1.8, 18–30
Proximate to death MMSE 27, 3.1, 0–30
Baseline global cognition 0.07, 0.45, −1.85 to 1.38
Proximate to death global cognition −0.14, 0.55, –2.45 to 1.28
Amyloid 3.16, 3.93, 0–22.9
Tangles 3.72, 4.22, 0–35.2
Gross infarcts (1+ present) 133, 29%
Microinfarcts (1+ present) 117, 25%
Neocortical Lewy bodies (present) 29, 6%
HETEROGENEITY OF AGE-RELATED COGNITIVE DECLINE AMONG OLDER
PERSONS WITHOUT DEMENTIA
We used random coefﬁcient models to characterize the annual
rate of decline (slope) in cognition; the primary outcome was the
longitudinal rate of change in global cognition, and this and all
subsequent analyses adjusted for age, sex, and education. In the
initial model, the global cognitive measure declined a mean of
about 0.034 unit per year (SE = 0.003, p = 0.0014). Figure 1
shows a spaghetti plot of raw data points for a random sample
(N = 50) of these participants Figure 1A as well as the model-
derived mean linear slope of cognitive decline (Figure 1B, dark
line) superimposed on the estimated individual slopes from the 50
individuals whose raw data points are shown. As the ﬁgure illus-
trates, most persons exhibited decline, but there was considerable
heterogeneity in person-speciﬁc slopes.
RELATION OF AGE-RELATED NEUROPATHOLOGIES WITH THE RATE OF
GLOBAL COGNITIVE DECLINE
We ﬁrst examined the relation of each neuropathology with the
rate of global cognitive decline in separate models. In the initial
analysis, amyloid was associated with a faster rate of cognitive
decline, such that a one percent increase in amyloid was associated
with a 0.002 unit (SE = 0.0006, p < 0.001) faster rate of decline
in global cognition. Tangles (estimate = −0.003, SE = 0.0006,
p < 0.001) and neocortical Lewy bodies (estimate = −0.024,
SE = 0.009, p = 0.015) also were associated with a faster rate
of decline. Macroscopic and microinfarcts were not signiﬁcantly
associated with the rate of decline.
Next, because previouswork suggests that the neuropathologies
of the threemost common causes of dementia frequently co-occur
andmixed pathologies are most strongly associated with cognitive
decline, we examined the relation of all of the neuropathologies
simultaneously with the slope of global cognitive decline. When
considered together, amyloid (estimate = −0.0014, SE = 0.0006,
p< 0.023), tangles (estimate = −0.0023, SE = 0.0006, p< 0.001),
and neocortical Lewy bodies (estimate = −0.0243, SE = 0.0096,
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FIGURE 1 |The panel(A) shows a spaghetti plot of individual trajectories from a random sample of persons (N = 50, raw data points plotted for each
individual) and the panel(B) shows the mean slope of cognitive decline superimposed on their estimated individual slopes (model-derived).
p = 0.011) remained associated with faster rates of decline.
Figure 2 is based on the fully adjusted model and illustrates the
additive effect of these neuropathologies on the rate of cognitive
decline. This ﬁgure shows that AD pathology (i.e., the mean of
amyloid and tangles) is associated with an increased rate of decline
compared to the verymodest decline associatedwith no pathology,
but the rate of decline is greatest for persons with both AD pathol-
ogy and neocortical Lewy bodies. Figure 3 further illustrates the
relation of the severity of pathology with cognitive decline.
RELATION OF AGE-RELATED NEUROPATHOLOGIES WITH DECLINE IN
FOUR COGNITIVE SYSTEMS
Next, because it is possible that the neuropathologies of AD, CVD,
and LBD have differential effects on speciﬁc cognitive systems
among persons without dementia, we next examined the relation
of the neuropathologies with rates of decline in four speciﬁc cog-
nitive systems (i.e., episodic memory, semantic memory, working
memory, and perceptual speed). In models considering all neu-
ropathologies together, measures of AD were related to decline
in three of the four systems, including episodic memory (i.e.,
tangles), semantic memory (i.e., amyloid, tangles), and work-
ing memory (i.e., amyloid), and neocortical Lewy bodies were
related to semantic memory, working memory, and perceptual
speed (Table 2). Macroscopic infarcts were related to decline in
semantic memory only, and microinfarcts were not related to
decline in any of the cognitive systems.
RELATION OF REGIONALLY SPECIFIC NEUROPATHOLOGY WITH
COGNITIVE DECLINE
Finally, because it is possible that regionally speciﬁc neuropathol-
ogy may have differential effects on cognitive decline among
persons without dementia, we next examined the relation of the
neuropathologies with decline in a series of models examining
FIGURE 2 | Contributions of combinations of the neuropathologies to
cognitive decline (model-derived slopes; top line shows the minimal
decline associated with no pathology, the red line shows the increased
rate of decline associated with AD pathology, and the blue line shows
the increased rate of decline associated with LBD pathology).
mesial temporal and neocortical amyloid and tangles, respectively;
all analyses controlled for the presence of CVD and LBD. Both
mesial temporal (estimate=−0.0027, SE= 0.0009, p= 0.002) and
neocortical amyloid (estimate= −0.0019, SE= 0.0005, p< 0.001)
were related to global cognitive decline, as were mesial temporal
(estimate = −0.0008, SE = 0.0002, p < 0.001) and neocortical
tangles (estimate = −0.0037, SE = 0.0010, p < 0.001). Mesial
temporal and neocortical amyloid and tangles also were related
to decline in episodic memory and semantic memory, but only
amyloid was related to decline in working memory (both mesial
temporal and neocortical amyloid) and perceptual speed (mesial
temporal only; Table 3).
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FIGURE 3 | Relation of neuropathology to cognitive decline
(model-derived slopes) among a typical participant with a low burden
of pathology (10th percentile amyloid = 0 and tangles = 0.311 and
negative for neocortical LBD) versus a participant with a high burden
of pathology (90th percentile amyloid = 9.262 and tangles = 8.048 and
positive for neocortical LBD).
DISCUSSION
We examined the burden and cognitive consequences of the neu-
ropathologies of the threemost common causes of dementia in old
age, AD, CVD, and LBD, in a cohort of more than 450 deceased
persons who were free of dementia at the time of death and had
detailed annual cognitive assessments for up to 18 years prior to
death. AD pathology was present in themajority of persons, about
a third had evidence of CVD, and a relatively small number had
neocortical Lewy bodies. Further, AD pathology and neocorti-
cal Lewy bodies were associated with an increased rate of decline
in global cognition, as well as multiple cognitive systems. These
ﬁndings suggest that the neuropathologies of the common causes
of dementia, particularly AD and neocortical LBD, are important
drivers of cognitive decline even amongpersonswithout dementia.
Prior studies have shown that the neuropathologies of the com-
mon causes of dementia are frequently found in the brains of
older persons without dementia. For example, upward of 30% of
older persons who die without a diagnosis of clinical dementia
meet pathologic criteria for AD, and the presence of pathologic
AD is related to cognitive decrements, particularly in episodic
memory (Crystal et al., 1988; Katzman et al., 1988; Riley et al.,
2002; Knopman et al., 2003; Bennett et al., 2006a). Further, we and
others have shown that the neuropathologies of AD (measured
continuously as done here), CVD, and LBD are common among
persons without dementia and even among persons without any
cognitive impairment (i.e., no dementia or mild cognitive impair-
ment) and are related to the level of cognitive function proximate
to death (Riley et al., 2002; Knopman et al., 2003; Bennett et al.,
2006a, 2012c). However, prior work has not elucidated the rela-
tion of these neuropathologies with longitudinal rates of change
in cognition among persons who die without dementia. The stud-
ies that examined the relation of neuropathology with cognitive
decline in persons without dementia typically used brief cogni-
tive assessments and/or had relatively small samples with short
lengths of follow-up, and all focused on a single pathology (e.g.,
Table 2 | Relation of the neuropathologies with rate of decline in four
cognitive systems*.
Term Estimate (SE) p
Episodic memory
Tangles –0.0045 (0.0009) p < 0.001
Amyloid Ns
Gross infarcts Ns
Microinfarcts Ns
Neocortical Lewy bodies Ns
Semantic memory
Tangles –0.0031 (0.0006) p < 0.001
Amyloid –0.0012 (0.0006) p = 0.044
Gross infarcts –0.0139 (0.0057) p = 0.016
Microinfarcts Ns
Neocortical Lewy bodies –0.0303 (0.0094) p = 0.001
Working memory
Tangles Ns
Amyloid –0.0021 (0.0007) p = 0.004
Gross infarcts Ns
Microinfarcts Ns
Neocortical Lewy bodies –0.0221 (0.0109) p = 0.042
Perceptual speed
Tangles Ns
Amyloid Ns
Gross infarcts Ns
Microinfarcts Ns
Neocortical Lewy bodies –0.0784 (0.0160) p < 0.001
*Derived from random coefﬁcientmodels including terms for age, sex, education,
time, all of the neuropathologies, and the interactions of demographics and the
neuropathologies with time.
AD, typically using Braak or other staging methods rather than
continuous measures as used here). The latter is a particularly
important limitation, given that mixed pathologies are common
and cognitive impairment in old age is most often due to mixed
neuropathologies (Green et al., 2000; Galvin et al., 2005; Driscoll
et al., 2006; Schneider et al., 2007; Balasubramanian et al., 2012).
Here, we extended prior work in three important ways: ﬁrst, we
examined the relation of neuropathology with the rate of cogni-
tive decline in global cognition measured using 17 cognitive tests,
as well as four speciﬁc cognitive systems; second, we studied a
relatively large cohort of older persons with repeated cognitive
assessments for up to 18 years; third, we examined multiple neu-
ropathologic indices of the threemost commoncauses of dementia
in old age, AD,CVD, and neocortical LBD.We found that the neu-
ropathologies of AD and neocortical LBD were associated with a
faster rate of decline in global cognition and multiple cognitive
systems among persons who died without dementia.
An understanding of the extent to which common neu-
ropathologies contribute to preclinical changes in cognition
is needed to facilitate efforts to prevent or delay the earliest
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Table 3 | Relation of the regionally specific neuropathology with rate
of decline in four cognitive systems*.
Term Estimate (SE) p
Episodic memory
Mesial temporal amyloid −0.0028 (0.0012) p = 0.025
Neocortical amyloid −0.0020 (0.0008) p = 0.0111
Mesial temporal tangles −0.0015 (0.0003) p < 0.001
Neocortical tangles −0.0059 (0.0014) p < 001
Semantic memory
Mesial temporal amyloid −0.0026 (0.0009) p = 0.004
Neocortical amyloid −0.0019 (0.0006) p = 0.001
Mesial temporal tangles −0.0009 (0.0002) p < 0.001
Neocortical tangles −0.0053 (0.0010) p < 0.001
Working memory
Mesial temporal amyloid −0.0029 (0.0010) p = 0.003
Neocortical amyloid −0.0017 (0.0006) p = 0.007
Mesial temporal tangles Ns
Neocortical tangles Ns
Perceptual speed
Mesial temporal amyloid −0.0031 (0.0014) p = 0.003
Neocortical amyloid Ns
Mesial temporal tangles Ns
Neocortical tangles Ns
*Derived from separate random coefﬁcient models including terms for age, sex,
education, time, CVD, LBD, the relevant regionally speciﬁc measure of pathology,
and the interactions of demographics and the pathologies with time.
manifestations of cognitive decline. Even very early andmild forms
of cognitive decline have important functional consequences; for
example, we have previously shown that cognitive decline among
persons without dementia or even mild cognitive impairment is
associated with impaired decision making and increased suscep-
tibility to scams (Boyle et al., 2012b). The present results support
the notion that cognitive decline begins well before the onset
of dementia and is related to the accumulation of the common
neuropathologies known to cause dementia. Further, multiple
cognitive abilities are affected by these neuropathologies, but
there was little evidence of regionally speciﬁc associations; that
is, both mesial temporal and neocortical amyloid and tangles
were related to global cognitive decline. In addition, whereas
both mesial temporal and neocortical amyloid and tangles were
related to decline in the domains of episodic memory and seman-
tic memory,mesial temporal and neocortical amyloid were related
to decline in working memory, and mesial temporal amyloid was
related to perceptual speed. The lack of regional associations is
consistent with the idea that cognitive abilities tend to become
increasingly correlated in late life as pathology accumulates (Boyle
et al., 2013) and is not surprising given that most of the data show-
ing region-speciﬁc associations come from lesion studies in which
there is damage to well-demarcated brain areas from organisms
with otherwise healthy brains. In addition, the regional mea-
sures of the pathology are relatively highly correlated. Thus, in the
context of age-related cognitive decline, which typically involves
multiple related neuropathologies, the association of pathology
with cognition may be of a more general nature.
The present ﬁndings suggest that at least some of the cognitive
decline observed among non-dementeds, that which is sometimes
considered “benign”, is in fact driven by pathologic processes and
highlight the important role the common neuropathologies play
in the early, preclinical phase of cognitive decline; thus, these data
underscore the need for therapies that can be utilized at the earliest
manifestation of symptoms or earlier, before irreversible dam-
age occurs. Identiﬁcation of the factors slow the rate of cognitive
decline in the face of accumulating neuropathology is urgently
needed. To date, scientiﬁc efforts have focused much less on the
factors that protect against cognitive decline and dementia than on
factors that predict dementia and other negative health outcomes,
andourunderstandingof themechanisms that allow somepersons
to remain dementia-free despite accumulating neuropathology is
still in its infancy. Several positive lifestyle (e.g., participation in
cognitive, physical, and social activities) and psychosocial factors
(e.g., extraversion, purpose in life, lifespace) have been shown to be
protective against the risk of dementia and rate of cognitive decline
(Wilson et al., 2002, 2007; Bennett et al., 2006b; Boyle et al., 2010,
2012a; James et al., 2011; Buchman et al., 2012;Wilson et al., 2012).
Some of these (e.g., purpose in life, social networks) modify the
association of AD pathology with cognitive function, such that
persons high in the protective factor function better cognitively
despite the burden of neuropathology (Bennett et al., 2006b; Boyle
et al., 2012a). However, the neurobiologic mechanisms underlying
the protective effects of these lifestyle and psychosocial factors
have yet to be identiﬁed. The concept of cognitive or neural
reserve posits that individual differences in the ability to toler-
ate or respond to accumulating pathology affect the degree to
which pathologic processes are expressed as decline or impair-
ment (Stern, 2002). Given that the neuropathologies of AD, CVD,
and neocortical LBDwere relatively frequent in the non-demented
persons included in this study, reserve may somehow have pro-
tected them from developing overt dementia. In keeping with this
idea, in a prior study, we found that neuronal density in the locus
coeruleus was associated with a reduced rate of cognitive decline
after controlling for AD, CVD, and LBD (Wilson et al., 2013). We
also found that presynaptic proteins were associated with bet-
ter cognition proximate to death and a slower rate of cognitive
decline after controlling forAD,CVD,and LBD (Honer et al., 2012;
Boyle et al., 2013). Increased research focus is needed to elucidate
the mechanisms by which indices of reserve operate to protect
against cognitive decline and dementia in the face of accumulating
neuropathology.
The study has strengths and limitations. Strengths are that all
subjects were recruited from the community and known to be free
of dementia proximate to death, all underwent detailed annual
cognitive evaluations forup to18 years, and autopsy rateswere very
high. In addition, all post-mortem evaluations were performed by
experienced and trained examiners shielded to all clinical data and
multiple biologically speciﬁc measures of pathology were quanti-
ﬁed. The study also has limitations. For example, the ﬁndings
are from a selected cohort and their generalizability remains to
be demonstrated. Future work is needed to better understand the
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impact of the common causes of dementia as well as protective
factors that inﬂuence cognition in population-based studies of
older persons who remain free of dementia throughout life.
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